Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Schizophrenic Psychoses Clear all

Conditions: Schizophrenia
Interventions: repetitive transcranial magnetic stimulation (rTMS), sham stimulation; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: NSA-789 at 2 different doses; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cocaine-Related Disorders, Substance-Related Disorders, Shcizophrenia
Interventions: Amantadine; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1999
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Aripiprazole (Abilify®) IM Depot Injection; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 119
States / cities: Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more

Conditions: Schizophrenia
Interventions: Risperidone, RBP-7000; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Little Rock, Alaska • Long Beach, California

Conditions: Schizophrenia
Interventions: Oxytocin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Schizophrenia
Interventions: Talnetant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 20
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 17 more

Conditions: Schizophrenia, Cognition, Cigarette Smoking
Interventions: tDCS; Device
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Schizophrenia
Interventions: Computer-Based Cognitive Enhancement Training Program, Work Therapy Program; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 20 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Glendale, California • Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Upland, California

Conditions: Schizophrenic Disorders, Cognitive Function
Interventions: Sodium Butyrate, Placebo; Dietary Supplement · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Conditions: Schizophrenic Disorders
Interventions: Psychiatric Rehabilitation Approach to Weight Loss; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Schizophrenia
Interventions: armodafinil, placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 12
States / cities: Garden Grove, California • National City, California • Paramount, California + 9 more

Conditions: Schizophrenia
Interventions: RBP-7000; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 41 more

Conditions: Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
Interventions: repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenic Disorders, Schizoaffective Disorder
Interventions: Intramuscular olanzapine depot; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 931 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 21
States / cities: Orange, California • Pasadena, California • San Diego, California + 18 more

Conditions: Schizophrenia, Schizo-affective Disorder
Interventions: Risperidone Implant; Drug
Lead sponsor: Braeburn Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Schizophrenia
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 20 more

Conditions: Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
Interventions: BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms, BXCL501 60 Micrograms; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more

Conditions: Schizophrenia
Interventions: Modafinil, Placebo; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Tobacco Use Disorder
Interventions: varenicline, Adaptation of Motivational Interviewing; Drug · Behavioral
Lead sponsor: VA Boston Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Brockton, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperdal Consta; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Repetitive Transcranial Magnetic Stimulation for "Voices"

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

Pharmacotherapy for Schizophrenic Drug Users - 6

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

Cognitive Training and Enhanced Supported Employment in Schizophrenia

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

Staccato Loxapine in Agitation (Proof of Concept)

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

The Psychiatric Rehabilitation Approach to Weight Loss

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia